GERN up +28.57% percent Today $GERN High is at 3.33 and the Low 2.96 with current volume of 13,830,619.
Recent News posted below.
Geron Corp GERN other info.
http://investorshangout.com/Geron-Corporation-GERN-54220/
GERN Geron Corp Recent Headline News
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - 22 mins ago
ZIOP: 3.73 (+0.44), BSPM: 1.40 (-0.33), BDR: 1.73 (+0.43), ZAZA: 2.92 (-0.63), ACY: 8.39 (-2.96), NBS: 6.20 (+0.81), SYRX: 1.37 (-0.93), IAG: 1.99 (+0.25), THTI: 1.30 (-0.39), BITA: 90.28 (+10.99), VRTB: 4.97 (+0.41), OPTT: 1.23 (+0.20), INVT: 0.88 (-0.34), GERN: 2.88 (+0.57), VASC: 24.41 (-6.09), LOCM: 1.54 (+0.23), CTHR: 1.73 (-0.89), MOV: 26.46 (-12.05), IFON: 1.38 (-0.49), SVM: 1.35 (+0.19)
Stock Market Today: Stocks Flat as Retail Sales Counter Eurozone Growth Woes
at The Street - 44 mins ago
U.S. stocks fluctuate on Friday, caught between better-than-expected retail sales and more worries of eurozone deflation.
SINA: 38.95 (-2.90), JNJ: 108.43 (-0.64), HTZ: 19.83 (-2.90), VA: 30.80 (+30.80), GERN: 2.88 (+0.57), JWN: 74.41 (+1.16)
Traders Get Bullish on Shares of Geron, Shares Up 28.6% (GERN)
Comtex SmarTrend(R) - 2 hrs 1 min ago
Geron (NASDAQ:GERN) is one of today's best performing low-priced stocks, up 28.6% to $2.97 on 5.5x average daily volume. Geron has traded 17.8 million shares thus far today, vs. average volume of 3.2 million shares per day. The stock has outperformed the Dow (28.6% to the Dow's -0.0%) and outperformed the S&P 500 (28.6% to the S&P's 0.1%) during today's trading.
GERN: 2.88 (+0.57)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 8:13AM CST
BDR: 1.73 (+0.43), GERN: 2.88 (+0.57), TUBE: 18.43 (+0.42), WYY: 1.44 (-0.14), YOD: 2.13 (-0.43), DGLY: 11.62 (-1.60), PBYI: 222.59 (-16.90), ENLK: 28.10 (-1.33), BHI: 58.83 (+0.08), SVM: 1.35 (+0.19)
Upgrade Alert for Geron (GERN)
Comtex SmarTrend(R) - Fri Nov 14, 7:57AM CST
Geron (NASDAQ:GERN) was upgraded from Neutral to Overweight at Piper Jaffray today. The stock closed yesterday at $2.31 on volume of 2.5 million shares, below average daily volume of 3.2 million. Geron share prices have moved between a 52-week high of $7.79 and a 52-week low of $0.91 and closed yesterday at 154% above that low price at $2.31 per share. Over the past week, the 200-day moving average (MA) has gone down 1.8% while the 50-day MA has declined 0.4%.
GERN: 2.88 (+0.57)
Geron up big premarket on J&J deal
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 7:55AM CST
GERN: 2.88 (+0.57)
Geron wins deal to develop blood disorder drug, could get $935M
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 4:55PM CST
JNJ: 108.43 (-0.64), GERN: 2.88 (+0.57)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 4:37PM CST
TSE: 12.02 (-1.72), WB: 18.95 (-0.67), VJET: 12.31 (+0.07), ALDW: 17.13 (-0.46), FRSH: 9.08 (+0.27), GERN: 2.88 (+0.57), TUBE: 18.43 (+0.42), XON: 22.72 (-1.05), RTRX: 9.82 (-1.80), PBYI: 222.59 (-16.90)
Geron could get $935M in blood disorder drug deal
AP - Thu Nov 13, 4:06PM CST
NEW YORK (AP) — Geron Corp. said Thursday it could get more than $900 million from a deal to develop its blood disorder drug imetelstat with a unit of Johnson & Johnson.
JNJ: 108.43 (-0.64), GERN: 2.88 (+0.57)
Geron Licenses Experimental Myelofibrosis Drug to Johnson & Johnson
at The Street - Thu Nov 13, 3:34PM CST
J&J is paying $35 million upfront to Geron for rights to the drug.
JNJ: 108.43 (-0.64), GERN: 2.88 (+0.57)
Geron Announces Global Strategic Collaboration with Janssen to Develop and Commercialize Imetelstat
Thomson Reuters ONE - Thu Nov 13, 3:15PM CST
Conference Call Scheduled for Friday Morning, November 14, 2014 at 8:30 AM EST
GERN: 2.88 (+0.57)
Geron's Risk/Reward Profile Improves As Near-Term Uncertainty Ends
Kanak Kanti De - at Seeking Alpha - Fri Nov 07, 12:06PM CST
GERN: 2.88 (+0.57)
Geron EPS in-line, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 3:28PM CST
GERN: 2.88 (+0.57)
After A Long Year, An Update on Geron's Myelofibrosis Drug is Disclosed
at The Street - Thu Nov 06, 8:57AM CST
he new imetelstat data in myelofibrosis are contained in a just-released research abstract ahead of next month's American Society of Hematology ASH annual meeting.
GERN: 2.88 (+0.57), INCY: 68.86 (-2.35)
Geron Announces Presentations at American Society of Hematology Annual Meeting
Thomson Reuters ONE - Thu Nov 06, 8:15AM CST
MENLO PARK, Calif., November 6, 2014 - Geron Corporation (Nasdaq: GERN) today announced that five abstracts describing clinical and non-clinical data on imetelstat have been accepted for presentation at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Francisco, California from December 6-9, 2014. The abstracts were published today on the ASH website at www.hematology.org.
GERN: 2.88 (+0.57)
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 8:46AM CST
It was another earnings-focused week with several biotech companies yet to report third quarter results.
VRTX: 111.96 (-0.76), GERN: 2.88 (+0.57), AMGN: 157.94 (-2.91), ABBV: 63.75 (+0.12), AEGR: 19.59 (-0.88), SNY: 46.64 (+0.11), REGN: 395.49 (-7.14)
Nasdaq stocks posting largest volume increases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
UMPQ: 17.61 (-0.03), HBNK: 19.95 (unch), BRDR: 7.95 (+0.61), SAPE: 24.70 (+0.02), TAIT: 0.96 (-0.07), BASI: 2.28 (-0.13), GERN: 2.88 (+0.57), NYMX: 0.50 (+0.01), MTEX: 21.89 (+0.15), CKEC: 28.51 (+0.03), ALQA: 5.06 (-0.03)
Most active Nasdaq-traded stocks
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SAPE: 24.70 (+0.02), FB: 74.48 (+0.23), PLUG: 3.76 (-0.30), GERN: 2.87 (+0.56), ODP: 6.81 (+0.09), ARCP: 8.70 (-0.11), INTC: 33.89 (+0.21), GRPN: 7.87 (+0.10), MSFT: 49.73 (+0.12), AAPL: 113.97 (+1.15), CSCO: 26.16 (+0.48)
Recent News posted below.
Geron Corp GERN other info.
http://investorshangout.com/Geron-Corporation-GERN-54220/
GERN Geron Corp Recent Headline News
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - 22 mins ago
ZIOP: 3.73 (+0.44), BSPM: 1.40 (-0.33), BDR: 1.73 (+0.43), ZAZA: 2.92 (-0.63), ACY: 8.39 (-2.96), NBS: 6.20 (+0.81), SYRX: 1.37 (-0.93), IAG: 1.99 (+0.25), THTI: 1.30 (-0.39), BITA: 90.28 (+10.99), VRTB: 4.97 (+0.41), OPTT: 1.23 (+0.20), INVT: 0.88 (-0.34), GERN: 2.88 (+0.57), VASC: 24.41 (-6.09), LOCM: 1.54 (+0.23), CTHR: 1.73 (-0.89), MOV: 26.46 (-12.05), IFON: 1.38 (-0.49), SVM: 1.35 (+0.19)
Stock Market Today: Stocks Flat as Retail Sales Counter Eurozone Growth Woes
at The Street - 44 mins ago
U.S. stocks fluctuate on Friday, caught between better-than-expected retail sales and more worries of eurozone deflation.
SINA: 38.95 (-2.90), JNJ: 108.43 (-0.64), HTZ: 19.83 (-2.90), VA: 30.80 (+30.80), GERN: 2.88 (+0.57), JWN: 74.41 (+1.16)
Traders Get Bullish on Shares of Geron, Shares Up 28.6% (GERN)
Comtex SmarTrend(R) - 2 hrs 1 min ago
Geron (NASDAQ:GERN) is one of today's best performing low-priced stocks, up 28.6% to $2.97 on 5.5x average daily volume. Geron has traded 17.8 million shares thus far today, vs. average volume of 3.2 million shares per day. The stock has outperformed the Dow (28.6% to the Dow's -0.0%) and outperformed the S&P 500 (28.6% to the S&P's 0.1%) during today's trading.
GERN: 2.88 (+0.57)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 8:13AM CST
BDR: 1.73 (+0.43), GERN: 2.88 (+0.57), TUBE: 18.43 (+0.42), WYY: 1.44 (-0.14), YOD: 2.13 (-0.43), DGLY: 11.62 (-1.60), PBYI: 222.59 (-16.90), ENLK: 28.10 (-1.33), BHI: 58.83 (+0.08), SVM: 1.35 (+0.19)
Upgrade Alert for Geron (GERN)
Comtex SmarTrend(R) - Fri Nov 14, 7:57AM CST
Geron (NASDAQ:GERN) was upgraded from Neutral to Overweight at Piper Jaffray today. The stock closed yesterday at $2.31 on volume of 2.5 million shares, below average daily volume of 3.2 million. Geron share prices have moved between a 52-week high of $7.79 and a 52-week low of $0.91 and closed yesterday at 154% above that low price at $2.31 per share. Over the past week, the 200-day moving average (MA) has gone down 1.8% while the 50-day MA has declined 0.4%.
GERN: 2.88 (+0.57)
Geron up big premarket on J&J deal
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 7:55AM CST
GERN: 2.88 (+0.57)
Geron wins deal to develop blood disorder drug, could get $935M
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 4:55PM CST
JNJ: 108.43 (-0.64), GERN: 2.88 (+0.57)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 4:37PM CST
TSE: 12.02 (-1.72), WB: 18.95 (-0.67), VJET: 12.31 (+0.07), ALDW: 17.13 (-0.46), FRSH: 9.08 (+0.27), GERN: 2.88 (+0.57), TUBE: 18.43 (+0.42), XON: 22.72 (-1.05), RTRX: 9.82 (-1.80), PBYI: 222.59 (-16.90)
Geron could get $935M in blood disorder drug deal
AP - Thu Nov 13, 4:06PM CST
NEW YORK (AP) — Geron Corp. said Thursday it could get more than $900 million from a deal to develop its blood disorder drug imetelstat with a unit of Johnson & Johnson.
JNJ: 108.43 (-0.64), GERN: 2.88 (+0.57)
Geron Licenses Experimental Myelofibrosis Drug to Johnson & Johnson
at The Street - Thu Nov 13, 3:34PM CST
J&J is paying $35 million upfront to Geron for rights to the drug.
JNJ: 108.43 (-0.64), GERN: 2.88 (+0.57)
Geron Announces Global Strategic Collaboration with Janssen to Develop and Commercialize Imetelstat
Thomson Reuters ONE - Thu Nov 13, 3:15PM CST
Conference Call Scheduled for Friday Morning, November 14, 2014 at 8:30 AM EST
GERN: 2.88 (+0.57)
Geron's Risk/Reward Profile Improves As Near-Term Uncertainty Ends
Kanak Kanti De - at Seeking Alpha - Fri Nov 07, 12:06PM CST
GERN: 2.88 (+0.57)
Geron EPS in-line, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 3:28PM CST
GERN: 2.88 (+0.57)
After A Long Year, An Update on Geron's Myelofibrosis Drug is Disclosed
at The Street - Thu Nov 06, 8:57AM CST
he new imetelstat data in myelofibrosis are contained in a just-released research abstract ahead of next month's American Society of Hematology ASH annual meeting.
GERN: 2.88 (+0.57), INCY: 68.86 (-2.35)
Geron Announces Presentations at American Society of Hematology Annual Meeting
Thomson Reuters ONE - Thu Nov 06, 8:15AM CST
MENLO PARK, Calif., November 6, 2014 - Geron Corporation (Nasdaq: GERN) today announced that five abstracts describing clinical and non-clinical data on imetelstat have been accepted for presentation at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Francisco, California from December 6-9, 2014. The abstracts were published today on the ASH website at www.hematology.org.
GERN: 2.88 (+0.57)
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 8:46AM CST
It was another earnings-focused week with several biotech companies yet to report third quarter results.
VRTX: 111.96 (-0.76), GERN: 2.88 (+0.57), AMGN: 157.94 (-2.91), ABBV: 63.75 (+0.12), AEGR: 19.59 (-0.88), SNY: 46.64 (+0.11), REGN: 395.49 (-7.14)
Nasdaq stocks posting largest volume increases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
UMPQ: 17.61 (-0.03), HBNK: 19.95 (unch), BRDR: 7.95 (+0.61), SAPE: 24.70 (+0.02), TAIT: 0.96 (-0.07), BASI: 2.28 (-0.13), GERN: 2.88 (+0.57), NYMX: 0.50 (+0.01), MTEX: 21.89 (+0.15), CKEC: 28.51 (+0.03), ALQA: 5.06 (-0.03)
Most active Nasdaq-traded stocks
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SAPE: 24.70 (+0.02), FB: 74.48 (+0.23), PLUG: 3.76 (-0.30), GERN: 2.87 (+0.56), ODP: 6.81 (+0.09), ARCP: 8.70 (-0.11), INTC: 33.89 (+0.21), GRPN: 7.87 (+0.10), MSFT: 49.73 (+0.12), AAPL: 113.97 (+1.15), CSCO: 26.16 (+0.48)
